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Abstract
Objectives Evidence for the utility of the new Mycobacte-
rium tuberculosis (MTB) speciWc IFN- release assays in
diagnosing latent tuberculosis infection (LTBI) is growing.
However, data concerning conversion and reversion rates in
serial testing of healthcare workers (HCWs) with an inter-
feron- release assay are sparse.
Methods Between February 2007 and September 2009,
670 HCWs in the University Hospital of Porto, Portugal
were tested at least twice with QuantiFERON-TB® Gold
In-Tube (QFT) for LTBI. The tuberculin skin test (TST)
was performed simultaneously. QFT was considered posi-
tive if INF- ¸0.35 IU/mL. TST conversion was deWned
as an increase ¸10 or ¸6 mm compared to a baseline
TST <10 mm.
Results The second QFT was positive in 4.8% of the 376
HCWs with an INF- concentration at baseline below
0.1 IU/mL but in 48.8% of the 41 HCWs with an INF-
concentration of 0.2 to <0.35 IU/mL. Out of 74 HCWs with
a baseline INF- concentration ¸3.0 IU/mL, 4 (5.4%)
reversed while 27 out of 55 HCWs (49%) with a baseline
INF- concentration ¸0.35 to <0.7 IU/mL reversed to a
negative QFT. Those 61 HCWs with TST conversion
(increase ¸10 mm) were most often (78.7%) negative in
both consecutive QFTs.
Conclusion Our data suggests the use of an uncertainty
zone between 0.2 and 0.7 IU/mL in serial testing with QFT.
As long as the knowledge regarding disease progression in
QFT-positive persons is limited, persons pertaining to this
zone should be retested before being oVered preventive
chemotherapy.
Keywords Serial testing · Interferon- release assay · 
Tuberculosis · Healthcare workers
Introduction
The increased risk of tuberculosis (TB) in healthcare work-
ers is well known (Seidler et al. 2005). Therefore, screening
HCWs for latent TB infection (LTBI) and preventive che-
motherapy is a cornerstone of TB prevention programs
(CDC  2005). However, the conventional tuberculin skin
test (TST) has known limitations in accuracy and reliabil-
ity. Furthermore, interpretation of serial TST results is
complicated by non-speciWc variation and because of
its intradermal application, by potential boosting from
precedent tests (Pai et al. 2007). The development of the
interferon- (INF-) release assays (IGRA) is welcomed as
a means of overcoming this problem. The IGRAs allow
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ex-vivo testing and therefore are not prone to boosting. In
addition, the IGRAs are highly speciWc, giving them valu-
able advantages over the TST especially in Bacillus
Calmette-Guérin (BCG)-vaccinated populations (Diel et al.
2006; Nienhaus et al. 2008).
As with the TST, IGRA results are determined by sev-
eral factors: precision of measurement technique, intra-
personal biological variation, new infection (conversion),
transient infection (Ewer et al. 2006) or transition of
Mycobacterium tuberculosis (MTB) from replication to
a dormant state no longer stimulating cell-mediated
immune response (reversion). MTB cannot be directly
observed in the body. Therefore, its presence and replica-
tion activity can only be measured indirectly by antigen-
speciWc response in TST or IGRA. For the TST, it is
common sense that test interpretation in serial testing should
be based on a comparison between actual and previous
TST results. Depending on circumstances, an increase in
TST ¸6 mm (Menzies 1999) or ¸10 mm (ATS 2000) is
believed to indicate MTB presence and activity. Prelimi-
nary data showed that, similar to TST, an easy positive/
negative interpretation of serial IGRA is not warranted
(Pai et al. 2006) and a more sophisticated approach to
IGRA interpretation in serial testing is needed. However,
data on IGRA interpretation in serial testing is sparse.
The few published studies available are rather small,
allowing limited conclusions only (Hill et al. 2007;
Franken et al. 2007; Cummings et al. 2009). So far, diVerent
‘uncertainty zones’ for QuantiFERON-TB® Gold In-Tube
(QFT), one of the two commercially available IGRAs,
have been proposed. Based on the Indian data, a person
whose IFN- result increased from <0.20 and exceeded
0.50 IU/mL on the repeat test was considered to have a
‘true conversion’. Likewise, a person whose IFN- result
decreased from >0.50 and fell to <0.20 IU/mL was con-
sidered to have a ‘true reversion’ (Pai et al. 2009). Based
on South African data, it was suggested that an increase
in IFN- response from below 0.35 IU/mL to above
0.70 IU/mL for the QFT assay could be used to deWne
conversions (van Zyl-Smit et al. 2009). Because high
spontaneous reversion rates were reported, when the Wrst
QFT showed INF- between 0.35 and 0.7 IU/mL
(Yoshiyama et al. 2009), it is unknown to what extent
people falling into this category beneWt from chemother-
apy. In our follow-up study, we analyzed conversion and
reversion rates in serial testing of HCWs with QFT,
depending on baseline concentration of INF- and TST
variation as well as for diVerent deWnitions of conver-
sions and reversions. Assuming that a small variation in
baseline INF- concentration should not result in high
changes to the conversion and reversion rates, we tried to
derive an uncertainty zone around the cutoV for the QFT
to be used in serial testing.
Materials and methods
Study setting and study subjects
The population of this follow-up study comprises all work-
ers of the Hospital S. João who participated in TB screen-
ing from February 2007 through September 2009. The
hospital is located in the northern part of Portugal and
serves as a referral center for TB. On average, 250 TB
patients are treated per year and a total of 32,000 patients
are admitted for all diagnosis. In addition, there are about
500,000 outpatient contacts per year. As reported from a
previous study of the same hospital (Torres Costa et al.
2009), the annual incidence rate of active TB in Portuguese
HCWs (192 per 100,000) was about six times higher than
the one in the general population in Portugal (32/100,000)
in 2006.
In accordance with CDC guidelines, HCWs in infection
and TB wards are considered to be at high risk, workers
with regular patient contacts in the other wards are consid-
ered to be at medium risk and workers with no regular
patient contacts or no contacts to biological material are
considered to be at low risk (CDC 2005). Upon commence-
ment of employment, all workers are examined. HCWs
considered to be at high risk are evaluated annually. All
others are evaluated every second year or after known
exposure to patients with active TB.
TST and IGRA have been performed simultaneously.
TST was performed when the diameter of a previous TST
was below 15 mm or when no previous TST result was
known. A chest X-ray was performed when TST was
¸10 mm or IGRA was positive or in HCWs with TB symp-
toms.
BCG vaccination was assessed through the individual
vaccination register or by scars. Following the national vac-
cination plan, BCG vaccination for newborns is mandatory
in Portugal and until January 2000 was repeated if TST was
<5 mm (National Vaccination Plan 2009). Therefore, every
HCW has been vaccinated at least once.
TST was performed by trained personnel following stan-
dard procedures. In brief, 0.1 mL (2 TU) of puriWed protein
derivate (RT23; Statens Serum Institute, Copenhagen, Den-
mark) was injected intradermally at the volar side of the
forearm, and the transverse diameter of the induration was
read 72–96 h later. A diameter ¸10 mm was considered
positive. A conversion in TST was deWned as a TST ¸
10 mm and an increase of ¸10 mm or less stringent ¸6m m
compared to a previous TST < 10 mm (Menzies 1999, ATS
2000).
Blood for the IGRA was drawn during the same appoint-
ment during which the TST and an interview were con-
ducted. As IGRA, the QuantiFERON-TB® Gold In-Tube
(QFT) assay (Cellestis Limited, Carnegie, Australia) wasInt Arch Occup Environ Health (2011) 84:461–469 463
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administrated following the manufacturer’s protocol. Con-
centrations above 10 IU/mL were set to 10 IU/mL because
of imprecision of measurement at these high concentrations
(Pai et al. 2009). According to the manufacturers, an INF-
concentration ¸0.35 IU/mL after subtracting the NIL con-
trol is deWned as a positive test result. Four diVerent deWni-
tions for conversion and reversion were applied: (1)
transgression or regression over cutoV, (2) increase from
<0.2 to >0.7 IU/mL or decrease from >0.7 to <0.2 IU/mL,
(3) transgression or regression over cutoV plus change
¸0.35 IU/mL, and (4) transgression or regression over
cutoV plus change ¸0.50 IU/mL. Observers were blinded
to the results of the TST and vice versa.
Statistical analysis
For metric variables, box plots were drawn giving the
median as black line in the box and the 25 and 75 percen-
tiles as the boundaries of the box. Chi-square tests were
used for categorical data. Baseline INF- concentration was
categorized in small increments in order to observe at
which increment the highest change in conversion and
reversion rates occurs. The 95% conWdence intervals (CI)
for proportions were calculated. If the 95% CI did not over-
lap, diVerences between proportions were considered as
statistically signiWcant.
The participants gave informed consent to the participa-
tion in the study. No agreement of an ethics commission
was requested because data collection was performed dur-
ing routine screening procedure following normal work
protection standards (CDC 2005). For study purposes, no
additional tests were performed and it is not standard prac-
tice to seek ethical approval for the anonymous analysis of
routine data in Portugal.
Results
The study population comprises 679 persons working in
healthcare with two consecutive QFTs. The study period
covers February 2007 until September 2009. Indeterminate
results were observed in nine (1.3%) HCWs. One of these
nine HCWs had indeterminate results on both occasions.
The characteristics of the remaining 670 HCWs as well as
of a subgroup of 252 HCWs who had three consecutive
QFTs are given in Table 1. The subgroup is comparable to
the whole group with respect to the distribution of age, gen-
der, BCG history, profession, risk assessment, and number
of TSTs during the study period.
The Wrst and second QFTs were positive in 30.0% of the
HCWs (Table 2). A conversion occurred in 11.0% of those
negative in the Wrst QFT and a reversion in 22.1% of those
positive in the Wrst QFT, if a simple dichotomous approach
(negative-positive and vice versa) was chosen. Reversion
and conversion rates depended on the INF- concentration
of the Wrst QFTs. Conversion occurred in 4.8% of the 376
HCWs with an INF- concentration at baseline below
0.1 IU/mL but in 48.9% of the 41 HCWs with an INF-
Table 1 Description of the study population with two consecutive
QFTs and subpopulation with three consecutive QFTs
Two QFTs Three QFTs
N % N %
Age
16–29 269 40.1 95 37.7
30–39 175 26.1 68 27.0
40–49 115 17.2 49 19.4
50–59 92 13.7 34 13.5
¸60 19 2.8 6 2.4
Gender
Female 495 73.9 188 74.6
Male 175 26.1 64 25.4
BCG history
Only at birth 182 27.2 59 23.4
One additional 244 36.4 106 42.1
Two additional 177 26.4 54 21.4
¸3 additional 67 10.0 33 13.1
TB in history
Yes 79 11.8 28 11.1
No 591 88.2 224 88.9
Profession
Administrators 98 14.6 38 15.1
Auxiliaries, cleaning staV 108 16.1 49 19.4
Technicians 
(radiology, lab, etc.)
45 6.7 21 8.3
Nurses 307 45.8 110 43.7
Doctors 112 16.7 34 13.5
Risk assessment
Low 94 14.0 48 19.0
Moderate 246 36.7 80 31.8
High 330 49.3 124 49.2
Years working in hospital
<5 283 42.2 101 40.1
5 · 10 115 17.2 44 17.5
10 · 15 84 12.5 33 13.1
15 · 20 58 8.7 27 10.7
¸20 130 19.4 47 18.7
TST history in last 3 years
No TST, old, TST ¸15 mm 138 20.6 46 18.3
One TST 346 51.6 143 56.7
Two TSTs 150 22.4 52 20.6
Three TSTs 36 5.4 11 4.4
Total 670 100.0 252 100.0464 Int Arch Occup Environ Health (2011) 84:461–469
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concentration of 0.2 to <0.35 IU/mL. The same pattern is
observed for reversions. In the 49 HCWs with a baseline
INF- concentration >7.0 IU/mL, two reversions (4.1%)
occurred while in those 55 (34 + 21) HCWs with a baseline
INF- concentration ¸0.35 to <0.7 IU/mL, about every sec-
ond HCW showed a reversion. For reversion and conversion
rates, a neat dose-frequency relation to the concentration at
the Wrst QFT was observed.
The diameter of the TST was positively associated with
the probability of two consecutive positive QFTs. This
probability increased from 10% in those with a
TST <10 mm to 31.7% for those with a TST ¸15 mm
(Table 3). An increase in the second TST by at least 10 mm
was seen in 61 (30.7%) of those who had a Wrst
TST <10 mm. Of these 61 HCWs 78.7% were negative in
the two consecutive QFTs and 6.6% showed a conversion
in QFT (DeWnition 1). In those HCWs with a TST of
10 · 15 mm who were retested during the study period,
four (2.1%) showed decreases in their TST results of
¸10 mm and seven (4.5%) of ¸6 mm.
Conversion and reversion rates showed statistically sig-
niWcant diVerences, depending on the deWnition used
(Table 4). The conversion rates were highest following
TST (17.9%) and second highest when crossing the cutoV
for QFT was used as a deWnition. The 95% CI of these rates
does not overlap, indicating a statistically signiWcant diVer-
ence. Using a gray zone from 0.2 to 0.7 IU/mL and exclud-
ing all those who have at least one QFT within this gray
zone from calculation resulted in low conversion (3.6%)
and reversion rates (5.2%). Somewhat higher rates were
obtained when, in addition to a positive–negative approach,
a minimal chance of 0.35 or 0.5 IU/mL was requested for
conversion and reversion. For all deWnitions, conversion
rates were lower than reversion rates but the diVerence was
statistically signiWcant for the least stringent deWnition only
(1a + b, Table 4). For the TST, reversion rates (2.1 or 3.8%)
were considerably lower than conversion rates (17.9 or
22.8%).
In the subgroup with three consecutive QFTs, the same
trend was observed (Table 5) as in the whole study group.
However, the proportion of those who were positive
throughout all three QFTs dropped to 14.3% (36/252) from
24.2% (162/670) with two positive consecutive QFTs in the
whole group. Two (10%) reversions (one transient rever-
sion—second QFT negative and third QFT positive) were
observed in those with a baseline INF- concentration
¸3.0 IU/mL, while 73.3% showed a reversion at the second
(n = 10) or the third (n = 1) QFT when the baseline INF-
concentration was ¸0.35 to <0.7 IU/mL. In addition, one
(6.7%) transient reversion occurred. In Figs. 1 and 2, the
association between baseline INF- concentration and
reversion or conversion can also be seen. The median of the
baseline INF- concentration was ¸0.1 IU/mL in those
with conversion in the second or in the third QFT (Fig. 1).
Only one reversion occurred when the baseline INF- con-
centration was above 3.0 IU/mL (see asterisk in Fig. 2).
The time between the Wrst and second QFT was, on aver-
age, 11.5 months (standard deviation 4.0 months). The time
between the Wrst and third QFT was, on average,
19.8 months (standard deviation 5.5 months). No associa-
tion was observed between the time span of the QFTs and
Table 2 Results of second QFT depending on INF- concentration in
Wrst QFT
1st QFT (IU/mL) 2nd QFT Total
Negative Positive
N % N % N Col % (row %)
<0.1 358 95.2 18 4.8 376 81.4
0.1 · 0.2 32 71.1 13 28.9 45 9.7
0.2 · 0.35 21 51.2 20 48.8 41 8.9
Neg. 1st QFT 411 89.0 51 11.0 462 100.0 (69.0)
0.35 · 0.5 17 50.0 17 50.0 34 16.3
0.5 · 0.7 10 47.6 11 52.4 21 10.1
0.7–1.0 5 19.2 21 80.8 26 12.5
>1–3 10 18.9 43 81.1 53 25.5
>3–7 2 8.0 23 92.0 25 12.0
>7 2 4.1 47 95.9 49 23.6
Pos. 1st QFT 46 22.1 162 77.9 208 100.0 (31.0)
All 457 68.2 213 31.8 670 100.0
Table 3 Results of Wrst and second QFT in relation to TST and to
change in TST
* First TST <10 mm, second TST ¸10 mm and increase or decrease
compared to previous TST ¸10 (6) mm
% row percent, col % column percent
¡¡ both consecutive QFTs were negative
¡+ Wrst QFT was negative, second QFT was positive, and so on
TST 1st and 2nd QFT Total
¡¡ ++ +¡¡ +
N % N % N % N % N %
0–9 mm 67 74.4 9 10.0 9 10.0 5 5.6 90 13.4
10–14 mm 156 67.8 42 18.3 13 5.7 19 8.3 230 34.3
¸15 mm 188 53.7 111 31.7 24 6.9 27 7.7 350 52.2
Increase TST*
¸10 mm 48 78.7 4 6.6 5 8.2 4 6.6 61/199 30.7
¸6 mm 75 76.5 9 9.2 7 7.1 7 7.1 98/199 49.2
Decrease TST
¸10 mm 3 75.0 1 25.0 0 – 0 – 4/188 2.1
¸6 mm 4 57.1 2 28.6 0 – 1 14.3 7/188 4.5Int Arch Occup Environ Health (2011) 84:461–469 465
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the probability of conversion or reversion in the QFT (data
not shown).
Nine HCWs were diagnosed with active TB, all but two
were acid-fast bacillus (AFB)-positive, culturally con-
Wrmed cases. In one person, diagnosis was based solely on
PCR (Table 6). All persons with active TB were positive
in the Wrst QFT. The TST was ¸15 mm in seven and
10–14 mm in two of them. Seven HCWs had pulmonary
TB, one pleural TB, and one skin TB. Six active TB cases
were diagnosed within 2 months of the Wrst QFT. The
other three cases were diagnosed three, seven, and
19 months after the Wrst positive QFT. In one case, a sec-
ond QFT was performed at the time of diagnosis 3 months
after the Wrst QFT and an increase from 0.51 to 1.96 IU/mL
was observed. The median of the INF- concentration in
those with actual pulmonary TB was 2.26 IU/mL, the
minimum was 0.51 IU/mL, and the maximum 6.32 UI/mL.
For the HCW with pleural TB the INF- in the Wrst
Table 4 Number and rate of 
conversions and reversions 
depending on diVerent deWni-
tions for ‘true’ conversions and 
‘true’ reversions
DeWnition of (a) conversion (b) reversion Source 
population
N %9 5 %  C I
(1a) Transgression from <0.35 to ¸0.35 IU/mL 462 51 11.0 8.3–14.3
(1b) Regression from ¸0.35 to <0.35 IU/mL 208 46 22.1 16.7–28.4
(2a) Transgression from <0.2 to >0.7 IU/mL 421 15 3.6 2.0–5.8
(2b) Regression from >0.7 to <0.2 IU/mL 153 8 5.2 5.3–10.0
(3a) As deWned in (1a) plus increase ¸0.35 IU/mL 462 41 8.9 6.4–11.8
(3b) As deWned in (1b) plus decrease ¸0.35 IU/mL 208 33 15.9 11.2–21.6
(4a) As deWned in (1a) plus increase ¸0.50 IU/mL 462 31 6.7 4.6–9.4
(4b) As deWned in (1b) plus decrease ¸0.50 IU/mL 208 21 10.1 6.4–15.0
TST
(5a) First TST <10 mm, increase ¸10 mm 199 61 30.7 24.3–37.6
(5b) First TST ¸10 mm, decrease ¸10 mm 188 4 2.1 0.6–5.4
(6a) TST <10 mm, increase ¸6 mm 199 98 49.2 42.1–56.4
(6b) TST ¸10 mm, decrease ¸6 mm 188 7 3.8 1.5–7.5
Source population: Those who 
fulWlled the Wrst condition (posi-
tive or negative Wrst test) of the 
diVerent deWnitions for conver-
sion and reversion
N absolute number of converted 
or reverted HCWs
% annual rate of reversions and 
conversions
95% CI 95% conWdence interval
Table 5 Results of second and third QFT depending on INF- con-
centration in Wrst QFT
1st QFT
(IU/mL)
2nd and 3rd QFT Total
¡¡ ++ +¡¡ +
N (%) N (%) N (%) N (%) N (%)
<0.1 139 4 5 7 155
89.7 2.6 3.2 4.5 78.7
0.1 · 0.2 12 4 2 3 21
57.1 19.0 9.5 14.3 10.7
0.2 · 0.35 7 6 5 3 21
33.3 28.6 23.8 14.3 10.7
Neg. 1st QFT 158 14 12 13 197
80.2 7.1 6.1 6.6 100.0 (78.2)
0.35 · 0.7 10 3 1 1 15
66.6 20.0 6.7 6.7 27.3
0.7-1.0 1 4 1 0 6
16.7 66.7 16.7 – 10.9
>1–3 2 11 1 0 14
14.3 78.6 7.1 – 25.5
>3 1 18 0 1 20
5.0 90.0 – 5.0 36.4
Pos. 1st QFT 14 36 3 2 55
25.5 65.5 5.5 3.6 100.0 (21.8)
All 172 50 15 15 252
68.3 19.8 6.0 6.0 100.0
Fig. 1 Box plot for INF- concentration of the Wrst QFT depending on
whether all three consecutive QFTs were negative (¡ ¡ ¡), the third
QFT became positive (¡ ¡ +), only the second QFT was positive
(¡ + ¡) or the two following QFT were positive (¡ + +) for the
subgroup with a negative Wrst QFT (n = 197)
- + + - + - - - + - - -
Three consecutive QFTs
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QFT was 0.42 IU/mL and in the skin TB case it was
>10 IU/mL. After diagnosis and treatment, a reversion
occurred in the patient with pleural TB and a sharp
decline occurred in the HCW with cutaneous TB (>10–
1.04 IU/mL). For the other six cases, increases and
decreases of INF- concentration were observed three
times, respectively. A positive QFT led to diagnosis in
four HCWs with no symptoms. In the other 5 HCWs with
pulmonary, active TB, typical symptoms such as cough,
fever, weakness, or weight loss were observed along with
a positive QFT.
Discussion
Our study is the largest follow-up study for serial testing to
date. Furthermore, it is also the only study on serial testing
that actually observed active TB cases, thus allowing con-
clusions about test interpretation in serial testing to be
based on these Wndings. As suggested in smaller studies
before (Pai et al. 2006; Pai et al. 2009; Hill et al. 2007;
Franken et al. 2007; Yoshiyama et al. 2009; van Zyl-Smit
et al. 2009), our data shows that a simple positive/negative
approach in the interpretation of the IGRA might be mis-
leading because of a high number of spontaneous conver-
sions and reversions originating from INF- concentrations
close to the cutoV for the QFT. Using an uncertainty zone
around the cutoV would help to distinguish between clini-
cally unimportant variation and true conversion and rever-
sion. If one of the consecutive QFTs falls into this
uncertainty zone, conversion or reversion is doubtful. On
the basis of our data, the lower limit of the uncertainty zone
could be 0.2 IU/mL and the upper limit 0.7 IU/mL because
this provides the sharpest decrease in conversion and rever-
sion rates. Even though a reversion rate with initial INF-
concentration between 0.7 and ·1.0 was high (17.4%), the
uncertainty zone should not be extended to this range
because we observed an active pulmonary TB with an INF-
concentration of 0.92 IU/mL.
The conversion rate (11%) we observed was similar to
those reported for Indian HCWs (11.6%) (Pai et al. 2006).
In the Japanese HCW study, the conversion rate was lower
(1.7%) (Yoshiyama et al. 2009). In a recent German HCW
study, the conversion rate was 1.9% (Ringshausen et al.
2010). When applying the gray zone and deWning a
conversion as a transgression from <0.2 to >0.7 IU/mL, the
Table 6 Characteristics of the 9 HCWs diagnosed with active TB
* In all but the Wrst case, the second QFTs were performed after diagnosis
a Positive PCR, if not indicated otherwise all cases were AFB-positive and culturally conWrmed
b Culturally conWrmed
TB Gender Age TST mm 1st QFT IU/mL Months between 
1st QFT and diagnosis
2nd QFT 
IU/mL
Symptoms 
at Wrst QFT
Pneumal Female 26 17 0.51 3 1.96* None
Pneumal Female 39 18 3.97 <1 6.29 None
Pneumal Female 25 16 6.32 19 1.30 Cough
Pneumal Female 29 17 2.11 <1 3.28 Cough
Pneumal Female 25 13 1.30 <1 1.22 Cough, fever
Pneumal Female 31 22 0.92 7 0.56 Cough, weakness, 
weight loss
Pneumal Female 25 14 2.41 <2 3.57 None
Pleurala Male 26 20 0.42 <1 0.10 None
Cutaneousb Female 50 21 >10 <1 1.04 Skin lesion
Fig. 2 Box plot for INF- concentration of the Wrst QFT depending on
whether all three consecutive QFTs were positive (+ + +), the second
and third QFT became negative (+ ¡ ¡), only the second QFT was
negative (+ ¡ +) or the third QFT became negative (+ + ¡) for the sub-
group with a positive Wrst QFT (n =5 5 )
+ + - + - + + - - + + +
Three consecutive QFTs
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conversion rate decreased from 11 to 3.6%. We believe the
lower conversion rate to be more realistic because Portugal
is a country with medium TB incidence comparable to
Japan, while India is a high-incidence country. Therefore,
most conversions we observed are unlikely to be explained
by an increased replication rate of MTB (reactivation) or
new infection with MTB.
A conversion in TST (increase ¸10 mm) occurred about
three times as often as a conversion in QFT (30.7% versus
11%). Therefore, TST most likely overestimated the con-
version rate. Independent of the criteria, conversion of TST
was not predictive of a positive QFT. Three out of four
HCWs who fulWlled the criteria for TST conversion were
negative in the QFT. This casts some doubt on the validity
of the change criteria in serial testing with TST.
The reversion rate (22.1%) we observed was similar to
those reported for Indian HCWs (24%) (Pai et al. 2006). In
the Japanese HCW study, the reversion rate was higher
(52.6%) (Yoshiyama et al. 2009). In this study, 80% (eight
out of ten) of the reversions had at least one INF- concen-
tration falling into the above-deWned uncertainty zone. In
our data, spontaneous reversions were rare (4.1%) when
baseline INF- concentration was >7.0 IU/mL. The rever-
sion rate for a baseline INF- concentration between 1.0
and 3.0 IU/mL observed by us was about the same as that
observed in the Indian household contact study (18.9 versus
17%) (Pai et al. 2009). Even though this reversion rate is
high and is therefore unlikely to be explained by true rever-
sion (transition from T-cell stimulating replication to dor-
mant state of MTB), a QFT ¸ 1.0 should be considered as
indicative of LTBI because four out of our eight active TB
cases had baseline INF- concentrations between 1.0 and
3.0 IU/mL. One reason for the reversion rate being higher
than the conversion rate (22.1% versus 11%) might be the
‘tendency toward the mean’. In repeated testing, random
measurement errors tend to draw the results toward the
mean, which in our study was below 0.35I U/mL. Our data
suggest that this random measurement error is particularly
import around the cutoV.
A reversion in TST occurred Wve to ten times less often
than a reversion in QFT. Reversion in TST was not associ-
ated with reversion in QFT. Most often, those with a rever-
sion in TST were negative in both consecutive QFTs.
However, our data on reversion in TST is too sparse to
draw any meaningful conclusions.
Variability of INF- concentration is inXuenced by sev-
eral factors: intra-individual short-term variations of test
results, variation in precision of measurement techniques,
insuYcient standardization of the handling of the probes.
Variations caused by these factors can hardly be distin-
guished from variations caused by immunologic responses
to increasing or decreasing replication of MTB in the per-
sons infected. So far, only one study has measured short-
term variations in IGRA results. However, this study was
performed in a high-incidence country (van Zyl-Smit et al.
2009). Therefore, it was not possible to distinguish between
random variation of INF- and immunologic response to
MTB exposure. As a limitation of our data, we did not col-
lect data on variables that might inXuence the QFT results.
In future, studies are needed which analyze intra-individual
variation of IGRA results and risk factors for this variation
(e.g. alcohol consumption, time of test). Furthermore, vari-
ation of test results due to handling variations, diVerent test
kits or other technical aspects of the laboratory procedures
should be analyzed.
Studies on TB prediction by QFTs show promising
results in low to intermediate TB incidence countries (Diel
et al. 2008; Aichelburg et al. 2009; Yoshiyama et al. 2010).
In the Japanese prediction study, risk of progression to
active TB increased with the concentration of QFT
(Yoshiyama et al. 2010). So far, there is no study available
that describes the association between the changes in IGRA
and disease prediction. Only one of our nine TB cases was
diagnosed after a second QFT was performed. In this
patient, both QFTs were positive, with an increase from
0.51 to 1.96 UI/mL. This gives limited support to the
hypothesis that QFT variations might be predictive of TB
progression risk.
When using an uncertainty zone of 0.2–0.7 IU/mL, it
should be kept in mind that a QFT result around the
cutoV (0.35 IU/mL) does not exclude active TB. We
observed a pleural TB patient with an INF- concentra-
tion of 0.42 IU/mL. It is known that INF- response in
peripheral blood might be low in pleural TB patients
(Hooper et al. 2009). Therefore, this observation was not
surprising. Furthermore, we observed active pulmonary
TB in an HCW with a positive Wrst QFT falling into the
uncertainty zone and a second QFT clearly above the
uncertainty zone. It tells us that when using an uncer-
tainty zone in serial testing, this should be done with the
greatest of care. Uncertainty zone means that spontane-
ous, clinically irrelevant transgressions over the cutoV
are probably predominant, but it does not exclude LTBI
or even active TB. Sensitivity studies for QFT using
active TB as a surrogate for LTBI suggest that disease
activity might be inversely related to INF- concentra-
tion (Menzies et al. 2007; Diel et al. 2010). Therefore, as
with the TST, recent exposure and clinical symptoms
must be taken into account when interpreting QFT
results.
Progression rate for active TB is highest in the Wrst
2 years after exposure. Therefore, preventive treatment is
most eVective if recent infection is likely. In those with a
positive QFT result falling into the gray zone and recent
accidental and unprotected contact with infectious patients
or materials, QFT should be repeated within 4 weeks after468 Int Arch Occup Environ Health (2011) 84:461–469
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the Wrst test. If QFT remains positive, preventive treatment
should be initiated. If screening was performed because of
regular contact with TB patients or infectious materials and
therefore a distinction between old or recent LTBI is not
possible, the next routine screening and therefore the next
IGRA should be performed in 1 year. This recommendation
is based on weak evidence. It should be borne in mind that
low concentrations in QFT do not exclude progression to
active TB, as was observed in the above-mentioned Japanese
prediction study (Yoshiyama et al. 2010). However, disease
progression was more likely with higher INF- concentra-
tions in QFT. In future, studies are needed that analyze
progression risk depending on IGRA results, changes in
IGRA results, and exposure history.
Despite our increasing knowledge, several key ques-
tions about latent infection and reactivation of M. tuber-
culosis remain unanswered. Particularly, it should be
noted that both the TST and the IGRA are designed to
identify an adaptive immune response against M. tuber-
culosis, but not necessarily a latent infection. A positive
result of currently available diagnostic tests is primarily
a measure of an immunologic response to stimulation by
mycobacterial antigens that should not, therefore, be
equated with the presence of live M. tuberculosis in the
human host. The proportion of individuals who truly
remain infected with M. tuberculosis after TST or IGRA
conversion is unknown. It is also uncertain how long
adaptive immune responses toward mycobacterial anti-
gens persist in the absence of live mycobacteria. For
these reasons, according to the recently published
TBNET consensus statement regarding latent TB and
based on the informative value currently derived by
IGRA and TST, the term “latent infection” would at best
implicate “lasting tuberculosis immune responses” and
would not necessarily identify a true latent infection
with viable microorganisms and potential risk of devel-
oping active disease (Mack et al. 2009).
In conclusion, our data suggests the use of an uncertainty
zone between 0.2 and 0.7 IU/mL in serial testing with QFT.
As long as our knowledge regarding disease progression in
QFT-positive persons is limited, in countries with limited
experience in chemoprevention, persons pertaining to the
uncertainty zone should be retested before being oVered
preventive chemotherapy.
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